Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study)

Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study) - Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive-one (JALSG CML207study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000823

Enrollment

240

Registered

2007-09-15

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously untreated Chronic-phase chronic myelogenous leukemia

Interventions

imatinib imatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Previously untreated chronic phase CML 2. Age: 15=< <70 3. PS 0-3 (ECOG) 4. No severe major organ dysfunction 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Other active neoplasma 2. Severe infection 3. Anticancer drug other than hydoroxurea in 2 weeks 4. Severe psychological disorders such as shizophrenia 5. Pregnant and/or lactating woman 6. Uncontorlled diabetis meritis 7. Acute myocardial infarction in 1 year or history of heart failure 8. Liver chirosis 9. Otherwise eligible

Design outcomes

Primary

Measure	Time frame
Molecular response at 12 months of imatinib therapy	—

Secondary

Measure	Time frame
1 Overall survival at three years 2 Cytogenetic response at 2 years 3 Adverse events grade 3 and more	—

Countries

Japan

Contacts

Public ContactKoichi Miyamura

Japanese Red Cross Nagoya First Hospital Department of hematology

miyamu@nagoya-1st.jrc.or.jp052-481-511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026